MaxiVAX
Geneva, Switzerland ยท Science and Engineering
Source
Verified by Enterprise League
Data quality
Partial
Last verified
Jun 2023
Work here? Claim this profile
Overview
MaxiVAX SA is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immuno-therapy. Its treatment is capable of stimulating the natural immune response of the patient to eliminate cancer cells. Phase I clinical trials were completed with no safety issue, were well tolerated and with encouraging efficacy data.
The company received the 2017 CTI Swiss Medtech Award for its ground-breaking work, and its lead product, MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland. The company successfully filed an IND with the US FDA in 2018.
Contact Details
info@maxivax.ch
Geneva, Switzerland
Founded
2005
Employees
10-20
Categories
Keywords
You're invisible in searches for:
Add keywords that describe your company, services, or market to improve your visibility in search results.
Companies teams usually look at after MaxiVAX
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.